Researchers at The University of Texas MD Anderson Cancer Center have uncovered a potential therapeutic target for brain metastases in patients with aggressive inflammatory breast cancer. The study identifies soluble E-cadherin (sEcad) as a key driver of tumor spread to the brain, highlighting a novel role for the protein in promoting tumor invasion, resisting cancer cell death, and triggering brain inflammation through the CXCR2 signaling pathway.
Published in Neuro-Oncology, the study was led by Xiaoding Hu, M.D., Ph.D., instructor of Breast Medical Oncology, and Bisrat Debeb, D.V.M., Ph.D., associate professor of Breast Medical Oncology.
“This readily measurable blood biomarker plays a key role in driving brain metastasis,” said Debeb. “Targeting this pathway has tremendous potential to treat and prevent this serious complication and could help guide future therapies.”
Understanding the Role of sEcad in Brain Metastasis
Brain metastases are a frequent and deadly complication of advanced breast cancer, particularly in inflammatory breast cancer. Treatment options are limited due to incomplete understanding of the underlying biological mechanisms.
Previous research from the Debeb lab indicated that patients with higher levels of sEcad in their blood face an increased risk of brain metastasis, earlier onset of metastasis, and poorer overall survival. This prompted the team to investigate the role of sEcad more closely.
Key Findings from Preclinical Models
Using preclinical models of inflammatory breast cancer that overexpressed sEcad, the researchers observed:
- Increased metastatic burden and accelerated spread to the brain
- Reduced overall survival
- Activation of the CXCR2 signaling pathway, which fosters a pro-metastatic, inflammatory environment while helping cancer cells evade cell death
Notably, treatment with a CXCR2 inhibitor significantly reduced metastasis and improved survival in these models, suggesting the pathway could serve as a viable therapeutic target.
Implications for Patients
These findings indicate that monitoring sEcad levels in the blood could help identify patients at highest risk for brain metastasis. Moreover, therapies targeting sEcad or the CXCR2 pathway may offer a new strategy to slow or prevent cancer spread in patients with inflammatory breast cancer. Additional studies will be required to validate these results and develop effective treatment protocols.
The research was supported by the U.S. Department of Defense, METAvivor, National Cancer Institute, American Cancer Society, MD Anderson Cancer Center, and the State of Texas Grant for Rare and Aggressive Cancers. A complete list of authors and disclosures is available in the published study in Neuro-Oncology.
